Teva Presents New Phase 3 Efficacy, Safety and Tolerability Data from SOLARIS Trial Evaluating TEV-‘749 (olanzapine) as a Once-Monthly Subcutaneous Long-Acting Injectable for Adult Patients Diagnosed with Schizophrenia Read more
New Data Provide Treatment Insights into Options for Switching Adult Patients Diagnosed with Schizophrenia to UZEDY® (risperidone) Extended-Release Injectable Suspension from Perseris® (RBP-7000) Read more
Wireless Gas Detection Market is projected to grow at a CAGR of 7.2% from 2024 to 2031 | Exactitude Consultancy Read more
Chijet Motor Company Inc. Announces Issuance of Ordinary Shares to Holders of Contingent Value Rights Read more
Universe Pharmaceuticals INC Reports Financial Results for The First Six Months of Fiscal Year 2024 Read more
Haoxi Health Technology Limited Announces the Closing of a $12 Million Underwritten Follow-on Public Offering Read more
Squamous Cell Carcinoma Clinical Trial Pipeline Insights: 75+ Key Companies Investigating Their Lead Candidates to Improve the Treatment Space | DelveInsight Read more